Tapering of inhaled corticosteroids in stable T2-low asthma: A randomized trial of symptom- and biomarker trajectories

This randomized, open-label, multicenter trial investigated whether tapering of inhaled corticosteroids was non-inferior to the standard of care in 20 adult asthma patients with persistently low T2 biomarkers. The primary endpoint was change in ACQ score from baseline to week 16. Secondary endpoints included change from baseline to week 16 in FEV1, which was measured using a Vitalograph spirometer with Spirotrac software.